The first case of receiving a free prescription for the 31st new drug메이저사이트 ‘Rexraza’ developed in Korea came out of Busan.

According to Kosin University Gospel Hospital on the 24th, a man in his 60s recently diagnosed with stage 4a non-small cell lung cancer accompanied by epidermal growth factor receptor ( EGFR ) mutation and a woman in her 50s who were diagnosed with stage 1 lung adenocarcinoma a year ago and had a recurrence after undergoing surgery were registered as EAP patients No. 1 and 2 and received free prescriptions of ‘Lexraza ‘ .

Lexraza is a third-generation targeted anticancer drug that inhibits the proliferation and growth of lung cancer cells by interfering with the signaling of the EGFR receptor involved in the growth of lung cancer cells. It has been administered as a second option to lung cancer patients who developed T790M resistance after taking first- and second-generation drugs such as Iressa and Tarceva. At the end of last month, it was approved for expansion as a first-line treatment for locally advanced or metastatic non-small cell lung cancer in which EGFR exon 19 deletion or exon 21 ( L858R ) substitution mutations were confirmed.

Yuhan Corp. (000100) made its first application case about two weeks after it promised to supply ‘Rexraza’ for free as a first-line treatment until health insurance benefits were used.